Nymox Pharmaceutical Corporation (NASDAQ: NYMX) was founded in 1989 and is headquartered in Nassau, Bahamas. It is a biopharmaceutical company engaged in the research and development of drugs for the elderly.
Nymox Pharmaceutical Corporation (NYMX):
Nymox Pharmaceutical Corporation is a biopharmaceutical company dedicated to research and development of drugs for the elderly.
- Nymox Pharmaceutical is engaged in the marketing of NicAlert and TobacAlert test strips, which can (using test strips) test the use of tobacco products through urine or saliva.
- In addition, Nymox Pharmaceutical also provides AlzheimAlert to assist physicians in diagnosing Alzheimer’s disease through urinalysis.
- Nymox Pharmaceutical’s main product candidate is Fexapotide Triflutate (NX-1207), which is currently in phase III clinical trials for the treatment of prostatic hypertrophy and benign prostatic hyperplasia, and at the same time, in the phase II clinical trials for the treatment of low-grade localized prostate cancer.
Nymox Pharmaceutical sells its products in Canada, the United States, Europe and internationally.